36 research outputs found
ANTHRACYCLINE CARDIOTOXICITY IN NON-HODGKIN’S LYMPHOMA MEDIASTINAL MASS: A CASE REPORT
Anthracycline is often used for treatment of hematologic malignancies and solid tumors,
and the damage it causes to the heart muscle has long been known; therefore,
the cardiac toxicity, one of the treatment-related co-morbidities, has become an issue
for cancer survivors. Cardiotoxicity has been defined using various classifications. In
this paper we report the case of a man affected by follicular non-Hodgkin’s lymphoma,
which was first diagnosed in 2006 and had a second recurrence in 2012 with a mediastinal
mass: the patient was subjected to a new cycle of chemotherapy with anthracycline,
the follow-up exam showed a significant reduction of the mass, but the clinical
condition worsened and the ejection fraction of the left ventricle had a progressive reduction,
as seen in the cardiac-MRI test. Then, it was decided to discontinue therapy
with anthracycline, resulting in a clear recovery of systolic function of the left ventricle,
as seen in the following echocardiogram